Core Insights - The three principles proposed by the founder of Yidu Technology, Ms. Gong Rujing, emphasize that AI should not replace doctors, should remain contextually relevant, and should not abandon inclusivity in healthcare [1][9] - The forum held in Kuala Lumpur gathered global investment leaders and industry experts to discuss the future of AI in healthcare [1] Group 1: AI in Healthcare - Ms. Gong Rujing highlighted that there is no "universal AI," but rather precise solutions that fit into workflows, emphasizing the need for high-quality medical data and seamless integration into the entire diagnostic and treatment process [3][4] - Yidu Technology's "AI Medical Brain" YiduCore has processed over 6 billion medical records, establishing a robust foundation for AI applications in healthcare [4] - The company has developed over 1,000 intelligent agents covering various clinical needs, significantly improving efficiency and standardization in areas like oncology [4][6] Group 2: Inclusivity in Healthcare - The ultimate mission of AI in healthcare is to provide accessible and affordable health services to everyone, as stated by Ms. Gong Rujing [6] - Yidu Technology has participated in the development of health insurance projects across multiple provinces, offering insurance products with annual premiums as low as 100 yuan, benefiting millions [6][7] - The company has served over 40 million insured users, demonstrating the social equity driven by technology [6] Group 3: Globalization and Localization - Ms. Gong Rujing emphasized that globalization in AI healthcare should not be a mere replication of solutions but should involve "technology generalization + local adaptation" to create value with local partners [8] - Yidu Technology has implemented localized projects, such as the BruHealth digital health platform in Brunei, covering over 60% of the population [8] - The company is also involved in Singapore's "MIC@Home" project, supporting remote monitoring and management of discharged patients [8]

Core Points - Yidu Tech (02158) shares rose over 6%, currently up 6.27% at HKD 7.12, with a trading volume of HKD 112 million [1] - The company announced that its affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately RMB 55.82 million [1] - At the "First Medical Artificial Intelligence Conference and Health Industry AI Application and Development Exhibition" held in Jinan, Dr. Li Linfeng, Vice President of Technology Innovation and AI Architect at Yidu Tech, introduced the "Doctor Copilot" built on the foundation of "big data + Yidu domain-specific large model," which has been implemented in several hospitals to enhance diagnostic efficiency and quality, aiding in the intelligent and standardized upgrade of clinical practices [1] Summary by Categories Financial Performance - Yidu Tech's stock price increased by 6.27%, reaching HKD 7.12, with a trading volume of HKD 112 million [1] Project Development - The company secured a project worth approximately RMB 55.82 million for the Phase III clinical research of SMR001 eye drops [1] Technological Innovation - The "Doctor Copilot" technology, which integrates clinical workflows, has been successfully implemented in multiple hospitals, improving diagnostic efficiency and quality [1]

消息面上，医渡科技公布，近期，公司联属公司天津开心生活科技有限公司中标山东衍渡生物科技有限 公司重组人神经生长因子(SMR001)滴眼液Ⅲ期临床研究项目，项目总金额约为人民币5582万元。此 外，由《中国卫生信息管理杂志》社主办的"首届医学人工智能大会暨卫生健康行业AI应用与产业发展 展览会"近日于济南举办。在大会"AI驱动医疗质量提升"论坛上，医渡科技技术创新副总裁、AI架构师 李林峰博士介绍，医渡科技以"大数据+医渡垂域大模型"为技术底座，构建了深度融合临床工作流的"医 生Copilot"。目前，医生Copilot已在多家医院落地应用，有效提升诊疗效率与质量，助力临床实现智能 化、规范化升级。 智通财经APP获悉，医渡科技(02158)涨超6%，截至发稿，涨6.27%，报7.12港元，成交额1.12亿港元。 ...